<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084041</url>
  </required_header>
  <id_info>
    <org_study_id>HOMECARE_CF</org_study_id>
    <nct_id>NCT04084041</nct_id>
  </id_info>
  <brief_title>Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis</brief_title>
  <official_title>Efficacy of the Simeox Airway Clearance Technology in the Treatment of Children With Clinically Stable Cystic Fibrosis- Cross-over Study With Randomization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Physio-Assist</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Physio-Assist</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chest physiotherapy plays a crucial role in treatment of lung disease in cystic fibrosis&#xD;
      (CF). New airway clearance techniques (ACTs) adapted to individual needs are still being&#xD;
      sought to achieve the best effect of airway clearance. The primary aim of this study is to&#xD;
      assess the efficacy of a new ACT (Simeox) on pulmonary function in children with CF. 40 CF&#xD;
      patients with stable respiratory function will be randomized 1:1 to Simeox or conventional&#xD;
      chest physiotherapy (CCPT) therapy (control group) and treated at home during 1 month. After&#xD;
      a short washout period, patients will be treated at home onto the alternative treatment for 1&#xD;
      month (crossover design). Lung function, quality of life, pulmonary exacerbation and safety&#xD;
      will be evaluated at 1 month for each therapy period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Actual">February 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total lung resistance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of R5hz - Impulse Oscillometry (IOS) from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central lung resistance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of R20hz - Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral lung resistance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of R5-20hz - Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lung reactance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of X5hz -Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in area of reactance (AX)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of AX -Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total score of Cystic Fibrosis Questionnaire-Revised (CFQ-R)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of CFQ-R total score (0-100) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in respiratory domain score of Cystic Fibrosis Questionnaire Revised (CFQ-R) questionnaire</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of respiratory score (0-100) of CFQ-R from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of FEV1 (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of FVC (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Residual Volume (RV)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of RV (body plethysmography) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximal Expiratory Flow (MEF) at 25, 50 and 75% of expired volume</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of MEF 25, 50 and 75 (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Mid Expiratory Flow (MMEF)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of MMEF (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lung clearance index (LCI)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of LCI with Nitrogen multiple breath washout (N2MBW) tests from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary exacerbation</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of pulmonary exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of adverse events related or not related to intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cystic Fibrosis in Children</condition>
  <condition>Airway Clearance Impairment</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional chest physiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Simeox</intervention_name>
    <description>Airway clearance device</description>
    <arm_group_label>Conventional chest physiotherapy</arm_group_label>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CCPT</intervention_name>
    <description>Conventional chest physiotherapy</description>
    <arm_group_label>Conventional chest physiotherapy</arm_group_label>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject and his or her legally appointed and authorized representative will agree for&#xD;
             treatment with Simeox technology&#xD;
&#xD;
          -  willing and able to cooperate and learn new technic of drainage.&#xD;
&#xD;
          -  age 8-18 years, on the date of admission to hospital.&#xD;
&#xD;
          -  confirmed diagnosis of CF as determined by the investigator.&#xD;
&#xD;
          -  able to perform pulmonary tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        History of any illness or any clinical condition that, in the opinion of the investigator,&#xD;
        might confound the cooperation or the results of the study or pose an additional risk to&#xD;
        the subject in using study technology. This includes, but is not limited to, the following:&#xD;
&#xD;
          -  contraindications to bronchial chest physiotherapy&#xD;
&#xD;
          -  hemoptysis&#xD;
&#xD;
          -  pneumothorax&#xD;
&#xD;
          -  heart disease&#xD;
&#xD;
          -  recent chest surgery&#xD;
&#xD;
          -  recent chest injury&#xD;
&#xD;
          -  history of lung transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorota Sands, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMiD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMiD</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Airway clearance technique</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

